RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31

Arcus Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$22.14+0.02 (+0.09%)

Close on Oct 19, 2026

Market cap: $2.79B
P/E (TTM): –
Dividend yield: –

Arcus Biosciences, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Cash & Equivalents	222	150	127	206	148	173	58	71	98	65	47
Short-Term Investments	759	828	632	803	351	555	–	–	–	–	–
Cash & Short-Term Investments	981	978	759	1,009	499	729	58	71	98	65	47
Prepaid Expenses & Other	15	18	34	19	18	5.47	4.05	2.32	1.14	–	–
Total Current Assets	1,007	1,016	831	1,067	1,262	736	193	259	177	–	–
Property, Plant & Equipment	40	47	51	35	32	11	9.33	11	11	–	–
Gross Property, Plant & Equipment	90	88	82	58	50	25	21	19	15	–	–
Accumulated Depreciation	-50	-41	-31	-23	-18	-14	-11	-7.64	-3.98	–	–
Long-Term Investments	29	14	107	129	182	6.44	–	–	–	–	–
Equity Method Investments	–	–	–	–	–	–	–	1.20	0.68	–	–
Operating Lease Right-of-Use Assets	58	65	92	100	105	13	–	–	–	–	–
Other Long-Term Assets	63	73	106	114	116	6.25	0.87	0.28	1.50	–	–
Total Assets	1,139	1,150	1,095	1,345	1,592	772	203	275	190	–	–
Accounts Payable	42	18	17	20	10	16	4.70	3.10	3.82	–	–
Accrued Expenses	–	–	–	–	24	9.54	4.95	6.02	3.14	–	–
Current Portion of Leases	13	12	11	3.00	5.10	2.87	–	–	–	–	–
Current Income Taxes Payable	1.00	1.00	0	0	2.00	–	–	–	–	–	–
Deferred Revenue (Current)	35	85	91	97	102	75	7.00	6.25	5.00	–	–
Other Current Liabilities	154	123	76	76	54	3.57	1.48	1.56	0.77	–	–
Total Current Liabilities	231	226	184	193	166	122	23	17	13	–	–
Long-Term Leases	86	99	110	117	117	15	–	–	–	–	–
Operating Lease Liabilities	99	111	121	126	114	18	–	–	–	–	–
Other Long-Term Liabilities	135	157	142	140	122	0.54	0.81	1.79	0.57	–	–
Total Liabilities	508	665	633	688	750	270	39	40	37	–	–
Preferred Stock	–	–	–	0	0	0	0	0	–	–	–
Common Stock	2,116	1,617	1,311	1,206	1,118	0.01	0.00	0.00	–	–	–
Additional Paid-In Capital	–	–	–	–	1,118	830	369	358	0.95	–	–
Retained Earnings	-1,485	-1,132	-849	-542	-275	-328	-205	-123	-73	–	–
Comprehensive Income & Other	0	–	0	-7.00	-1.00	0.04	0.06	-0.11	-0.04	–	–
Shareholders' Equity	631	485	462	657	842	502	164	235	-72	-20	-2.17
Total Equity	631	485	462	657	842	502	164	235	-72	-20	-2.17
Total Liabilities & Equity	1,139	1,150	1,095	1,345	1,592	772	203	275	190	–	–
Shares Outstanding(shares)	125	92	76	73	71	65	46	45	4.09	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -415.4%
Net margin: -393.2%
Return on equity, FY2025: -63.3%

Financial strength

Current ratio: 3.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 75.8%

Valuation

P/E ratio: –
Price to sales: 23.86
Price to book: 6.02
Dividend yield: –